Dublin, May 24, 2017 -- Research and Markets has announced the addition of the "Social Media in Pharma" report to their offering.
Social media covers a range of different online, interactive sites, such as Facebook and Twitter, and these different platforms have a considerable reach and following, with many sites boasting millions of users and daily visits. Despite the rapidly growing popularity of social media, the pharmaceutical industry has been slow to embrace it, constrained by compliance and regulatory concerns and bound by a traditional reluctance for change.
However, the successes seen in other industries and the increasing use of social media by key customers - in particular patients and physicians - means that the pharmaceutical industry can no longer afford to ignore social media, and several companies have taken the leap with Facebook pages, Twitter accounts, and a YouTube presence.
Social media is constantly evolving and new sites are regularly emerging; however, it is expected that the longer-standing platforms such as Facebook and Twitter will continue to dominate, particularly in relation to the pharmaceutical industry. As such, most pharmaceutical companies are creating social media teams to both manage their online social media presence and ensure a robust strategy that takes advantage of the range of benefits that social media provides.
Social media gives pharmaceutical companies the opportunity to engage directly with patients and physicians and rapidly respond to questions, requests for information, and negative opinions on products. More advanced companies are utilizing social media to understand unmet needs, design clinical programs, and discover thought leaders. However, there is still a note of caution, with compliance being at the forefront of many pharmaceutical companies' minds, and, while the industry is starting to embrace social media and build on the many opportunities that it affords them, without clear finalized regulatory guidance, remaining compliant will continue to be main challenge facing the industry.
Key Topics Covered:
1. Executive Summary
2. Social Media in the Pharmaceutical Industry
- Social media is a relatively new method of communication
- Pharma-specific platforms are growing in popularity
- There is little legislation or regulation around social media for pharma Several pharma companies have pioneered the use of social media Bibliography
3. How is Social Media Being Used?
- Pharmaceutical companies use social media in a range of ways Patients use social media to obtain information and make connections Healthcare providers mainly use social media to stay informed Pharma does not tend to use social media to interact with payers Bibliography
4. The Future for Social Media in Pharma
- How will it evolve?
- Opportunities and challenges for pharmaceutical companies
Companies Mentioned
- YouTube
For more information about this report visit http://www.researchandmarkets.com/research/pfcvxc/social_media_in
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals, Social Media


SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom
Toyota Retains Global Auto Sales Crown in 2025 With Record 11.3 Million Vehicles Sold
Federal Judge Signals Possible Dismissal of xAI Lawsuit Against OpenAI
Tesla Q4 Earnings Beat Expectations as Company Accelerates Shift Toward AI and Robotics
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High
Amazon Stock Dips as Reports Link Company to Potential $50B OpenAI Investment
Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates
Microsoft AI Spending Surge Sparks Investor Jitters Despite Solid Azure Growth
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says
US Judge Rejects $2.36B Penalty Bid Against Google in Privacy Data Case
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations
Pentagon and Anthropic Clash Over AI Safeguards in National Security Use 



